COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020

Anna M Acosta; Adria L Mathis; Daniel S Budnitz; Andrew I Geller; Shua J Chai; Nisha B Alden; James Meek; Evan J Anderson; Patricia Ryan; Sue Kim; Kathryn Como-Sabetti; Salina Torres; Elizabeth Dufort; Nancy M Bennett; Laurie M Billing; Melissa Sutton; H Keipp Talbot; Andrea George; Huong Pham; Aron J Hall; Alicia Fry; Shikha Garg; Lindsay Kim

doi:10.1093/ofid/ofaa528

COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020

Open Forum Infect Dis. 2020 Nov 9;7(11):ofaa528. doi: 10.1093/ofid/ofaa528. eCollection 2020 Nov.

Authors

Anna M Acosta¹, Adria L Mathis^{1

2}, Daniel S Budnitz^{1

3}, Andrew I Geller^{1

3}, Shua J Chai^{3

4

5}, Nisha B Alden⁶, James Meek⁷, Evan J Anderson^{8

9

10}, Patricia Ryan¹¹, Sue Kim¹², Kathryn Como-Sabetti¹³, Salina Torres¹⁴, Elizabeth Dufort¹⁵, Nancy M Bennett¹⁶, Laurie M Billing¹⁷, Melissa Sutton¹⁸, H Keipp Talbot¹⁹, Andrea George²⁰, Huong Pham¹, Aron J Hall¹, Alicia Fry^{1

3}, Shikha Garg^{1

3}, Lindsay Kim^{1

3}

Affiliations

¹ COVID-NET Surveillance Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
² All Native Synergies Company, Winnebago, Nebraska, USA.
³ US Public Health Service, Rockville, Maryland, USA.
⁴ California Emerging Infections Program, Oakland, California, USA.
⁵ Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
⁶ Colorado Department of Public Health and Environment, Denver, Colorado, USA.
⁷ Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut, USA.
⁸ Emory University School of Medicine, Atlanta, Georgia, USA.
⁹ Georgia Emerging Infections Program, Atlanta, Georgia, USA.
¹⁰ Veterans Affairs Medical Center, Atlanta, Georgia, USA.
¹¹ Maryland Department of Health, Baltimore, Maryland, USA.
¹² Michigan Department of Health and Human Services, Lansing, Michigan, USA.
¹³ Minnesota Department of Health, St. Paul, Minnesota, USA.
¹⁴ New Mexico Department of Health, Santa Fe, New Mexico, USA.
¹⁵ New York State Department of Health, Albany, New York, USA.
¹⁶ University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
¹⁷ Ohio Department of Health, Columbus, Ohio, USA.
¹⁸ Oregon Health Authority, Portland, Oregon, USA.
¹⁹ Vanderbilt University Medical Center, Nashville, Tennessee, USA.
²⁰ Salt Lake County Health Department, Salt Lake City, Utah, USA.

Abstract

Using a coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1-June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.

Keywords: coronavirus; hospitalization; therapeutics.

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Grants and funding

NU38OT000297/CC/CDC HHS/United States